# Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT01238146** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Splenic Marginal Zone Lymphoma

## Interventions

- **DRUG:** bendamustine hydrochloride
- **DRUG:** obatoclax mesylate
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT01238146
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-10
- **Primary completion:** 2012-04
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients accrued.
- **Last updated:** 2013-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238146, "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01238146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*